跳到正文
Science Advances· Xiawen Liu, Xiufen Zheng, Lei Ma, Ziqing Yao, Xuehua Zheng, Miao Liang, Xinhong Wu, Silin Zhang, Xianglin Zhou, Leying Zhu, Zhi Zhou, H. Eric Xu, Wei Yi·· 7 天前AI 评分41

双效小分子 VSP-51-2 通过 PPARγ 调节与 AKR1C3 抑制改善多囊卵巢综合征

Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition

AI 导读

Science Advances 发表的研究显示,双效小分子 VSP-51-2 通过调节 PPARγ 并抑制 AKR1C3,改善多囊卵巢综合征。该结果提示 PPARγ 调节与 AKR1C3 抑制的双重作用可能成为多囊卵巢综合征的干预方向。

原文摘要

出版方登记 · Crossref

Polycystic ovary syndrome (PCOS), a prevalent multifactorial endocrine disorder, is inadequately managed by current therapies that fail to concurrently target its core metabolic (insulin resistance) and reproductive (hyperandrogenism) pathologies. We report VSP-51-2, a dual-target lead compound initially engineered as a selective PPARγ modulator that unexpectedly exerts potent uncompetitive inhibition of the androgen-synthesizing enzyme AKR1C3 through a putative allosteric mechanism. In preclinical PCOS models, VSP-51-2 restored regular estrous cyclicity, improved ovarian follicular morphology, enhanced systemic insulin sensitivity, suppressed hyperandrogenism, and did not significantly perturb measured hypothalamic-pituitary-ovarian (HPO) axis hormonal parameters. Mechanistically, it blocks PPARγ phosphorylation at Ser 273 , thereby enhancing adiponectin secretion and GLUT4-mediated glucose uptake, and is predicted to bind a putative allosteric pocket of AKR1C3 to constrain androgen biosynthesis. These findings support VSP-51-2 as a preclinical proof-of-concept compound for a dual-target strategy that addresses metabolic dysfunction and androgen excess through a unified molecular scaffold.

页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文

来源:Science Advances · science.org